Devonian Health Group, Inc. (TSE:GSD) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Devonian Health Group reported a significant 360% increase in first-quarter revenues, boosted by the success of its Altius subsidiary’s pharmaceutical product, DEXLANSOPRAZOLE. Despite the revenue surge, the company posted a net loss of $0.002 per share. Additionally, Devonian granted over 1.5 million stock options to its independent directors, signaling confidence in future growth.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.
